The simpleton's error in drug development.
Castro
Michael
M
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017322:Clinical Trials, Phase II as Topic; D015195:Drug Design; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors*; D066246:ErbB Receptors / Q000187:drug effects*; D000077156:Gefitinib; D006801:Humans; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011799:Quinazolines / Q000494:pharmacology*; D016032:Randomized Controlled Trials as Topic
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D011799:Quinazolines; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib